Engineering Papers⌕ Search

SEARCH · Engineering Papers

Results for “cervical”

Search indexed NASA NTRS and DOE OSTI research on propulsion, heat transfer, battery materials and energy systems. Follow report and document links to the original sources.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 595 records · Page 33

Dosimetric evaluation of PLATO and Oncentra treatment planning systems for High Dose Rate (HDR) brachytherapy gynecological treatments

This study compares the dosimetric differences in HDR brachytherapy treatment plans calculated with Nucletron's PLATO and Oncentra MasterPlan treatment planning systems (TPS). Ten patients (1 T1b, 1 T2a, 6 T2b, 2 T4) having cervical carcinoma, median age of 43.5 years (range, 34-79 years) treated with tandem and ring applicator in our institution were selected retrospectively for this study. For both Plato and Oncentra TPS, the same orthogonal films anterior-posterior (AP) and lateral were used to manually draw the prescription and anatomical points using definitions from the Manchester system and recommendations from the ICRU report 38. Data input for PLATO was done using a digitizer and Epson Expression 10000XL scanner was used for Oncentra where the points were selected on the images in the screen. The prescription doses for these patients were 30 Gy to points right A (RA) and left A (LA) delivered in 5 fractions with Ir-192 HDR source. Two arrangements: one dwell position and two dwell positions on the tandem were used for dose calculation. The doses to the patient points right B (RB) and left B (LB), and to the organs at risk (OAR), bladder and rectum for each patient were calculated. The mean dose and the mean percentage difference in dose calculated by the two treatment planning systems were compared. Paired t-tests were used for statistical analysis. No significant differences in mean RB, LB, bladder and rectum doses were found with p-values > 0.14. The mean percent difference of doses in RB, LB, bladder and rectum are found to be less than 2.2%, 1.8%, 1.3% and 2.2%, respectively. Dose calculations based on the two different treatment planning systems were found to be consistent and the treatment plans can be made with either system in our department without any concern.

61 RADIATION PROTECTION AND DOSIMETRY↗

Cellular membrane collapse by atmospheric-pressure plasma jet

Cellular membrane dysfunction caused by air plasma in cancer cells has been studied to exploit atmospheric-pressure plasma jets for cancer therapy. Here, we report that plasma jet treatment of cervical cancer HeLa cells increased electrical conductivity across the cellular lipid membrane and caused simultaneous lipid oxidation and cellular membrane collapse. We made this finding by employing a self-manufactured microelectrode chip. Furthermore, increased roughness of the cellular lipid membrane and sequential collapse of the membrane were observed by atomic force microscopy following plasma jet treatment. These results suggest that the cellular membrane catastrophe occurs via coincident altered electrical conductivity, lipid oxidation, and membrane roughening caused by an atmospheric-pressure plasma jet, possibly resulting in cellular vulnerability to reactive species generated from the plasma as well as cytotoxicity to cancer cells.

60 APPLIED LIFE SCIENCES↗

Cloning, Expression, Purification, Crystallization and Preliminary X-ray Analysis of Mycoplasma Genitalium Protein MG289

Mycoplasma genitalium is a human pathogen that is associated with nongonococcal urethritis in men and cervicitis in women. The cloning, expression, purification and crystallization of the protein MG289 from M. genitalium strain G37 are reported here. Crystals of MG289 diffracted X-rays to 2.8 {angstrom} resolution. The crystals belonged to the orthorhombic space group P2{sub 1}2{sub 1}2{sub 1}, with unit-cell parameters a = 49.7, b = 90.9, c = 176.1 {angstrom}. The diffraction data after processing had an overall R{sub merge} of 8.7%. The crystal structure of Cypl, the ortholog of MG289 from M. hyorhinis, has recently been determined, providing a reasonable phasing model; molecular replacement is currently under way.

36 MATERIALS SCIENCE↗

Interindividual variability of arterial impulse response to intravenous injection of nonionic contrast agent (Iohexol) in DCE-CT study

Purpose: It is known that the arterial input function (AIF) in dynamic contrast-enhanced (DCE)-CT differs among patients even for fixed contrast injection protocols. Therefore, a study has been performed to investigate the interindividual variability of the AIF with respect to patient factors (such as weight, height, and age). In addition, it has been demonstrated that the relations from the interindividual variability investigation can be further used for the estimation of AIF for a patient without the requirement of measurement. Methods: DCE-CT data for a cohort of 34 patients with cervical carcinoma were used for the investigation of interindividual variability of the AIF. To dissociate the effect of different durations of contrast injection, the arterial impulse response (AIR) to intravenous contrast injection was calculated and examined for its correlations with these patient factors. An empirical functional form was proposed to model the AIR with temporal intensity of a first pass of contrast agent followed by recirculation and quasiequilibrium state of contrast concentration. Specific features (onset time, peak time, and amplitudes) of the AIR were tested for correlations with the patient factors. Linear regression was applied to cases that show significant strong correlation between the AIR amplitudes and patient factors. The results were then used to predict the AIR for any given patient based on the patient factors. It was shown that using the predicted AIR, the AIF of the patient can be estimated without the requirement of measurement given the injection protocol is known. The method of AIF estimation was tested in DCE-CT data from another group of 14 patients. The efficacy of individually estimated AIF on pharmacokinetic analysis was assessed against the use of measured AIF and population-averaged AIF as the latter is another possible strategy for AIF generation if AIF measurement is not available. Results: It was found that the amplitudes of AIR postonset time were significantly correlated with patient bodyweight at most time points (r<-0.44, P<0.01) except 8-17 s (P>0.01). When the adiabatic tissue homogeneity (ATH) and the Kety models were applied to the pharmacokinetic analysis, the mean percentage errors in kinetic parameter estimates induced by using the estimated AIF instead of the measured one for both models ranged from -4.98% to 11.19%. Conclusions: It was found that there are strong linear relationships between AIR and patient weight; thereby the AIR of a patient can be estimated with patient weight. The proposed method of AIF estimation is potentially applicable in cases where AIF measurement is not possible.

62 RADIOLOGY AND NUCLEAR MEDICINE↗

In-patient to isocenter KERMA ratios in CT

Purpose: To estimate in-patient KERMA for specific organs in computed tomography (CT) scanning using ratios to isocenter free-in-air KERMA obtained using a Rando phantom.Method: A CT scan of an anthropomorphic phantom results in an air KERMA K at a selected phantom location and air kerma K{sub CT} at the CT scanner isocenter when the scan is repeated in the absence of the phantom. The authors define the KERMA ratio (R{sub K}) as K/ K{sub CT}, which were experimentally determined in a Male Rando Phantom using lithium fluoride chips (TLD-100). R{sub K} values were obtained for a total of 400 individual point locations, as well as for 25 individual organs of interest in CT dosimetry. CT examinations of Rando were performed on a GE LightSpeed Ultra scanner operated at 80 kV, 120 kV, and 140 kV, as well as a Siemens Sensation 16 operated at 120 kV. Results: At 120 kV, median R{sub K} values for the GE and Siemens scanners were 0.60 and 0.64, respectively. The 10th percentile R{sub K} values ranged from 0.34 at 80 kV to 0.54 at 140 kV, and the 90th percentile R{sub K} values ranged from 0.64 at 80 kV to 0.78 at 140 kV. The average R{sub K} for the 25 Rando organs at 120 kV was 0.61 {+-} 0.08. Average R{sub K} values in the head, chest, and abdomen showed little variation. Relative to R{sub K} values in the head, chest, and abdomen obtained at 120 kV, R{sub K} values were about 12% lower in the pelvis and about 58% higher in the cervical spine region. Average R{sub K} values were about 6% higher on the Siemens Sensation 16 scanner than the GE LightSpeed Ultra. Reducing the x-ray tube voltage from 120 kV to 80 kV resulted in an average reduction in R{sub K} value of 34%, whereas increasing the x-ray tube voltage to 140 kV increased the average R{sub K} value by 9%. Conclusions: In-patient to isocenter relative KERMA values in Rando phantom can be used to estimate organ doses in similar sized adults undergoing CT examinations from easily measured air KERMA values at the isocenter (free in air). Conversion from in-patient air KERMA values to tissue dose would require the use of energy-appropriate conversion factors.

61 RADIATION PROTECTION AND DOSIMETRY↗

iCycle: Integrated, multicriterial beam angle, and profile optimization for generation of coplanar and noncoplanar IMRT plans

Purpose: To introduce iCycle, a novel algorithm for integrated, multicriterial optimization of beam angles, and intensity modulated radiotherapy (IMRT) profiles. Methods: A multicriterial plan optimization with iCycle is based on a prescription called wish-list, containing hard constraints and objectives with ascribed priorities. Priorities are ordinal parameters used for relative importance ranking of the objectives. The higher an objective priority is, the higher the probability that the corresponding objective will be met. Beam directions are selected from an input set of candidate directions. Input sets can be restricted, e.g., to allow only generation of coplanar plans, or to avoid collisions between patient/couch and the gantry in a noncoplanar setup. Obtaining clinically feasible calculation times was an important design criterium for development of iCycle. This could be realized by sequentially adding beams to the treatment plan in an iterative procedure. Each iteration loop starts with selection of the optimal direction to be added. Then, a Pareto-optimal IMRT plan is generated for the (fixed) beam setup that includes all so far selected directions, using a previously published algorithm for multicriterial optimization of fluence profiles for a fixed beam arrangement Breedveld et al.[Phys. Med. Biol. 54, 7199-7209 (2009)]. To select the next direction, each not yet selected candidate direction is temporarily added to the plan and an optimization problem, derived from the Lagrangian obtained from the just performed optimization for establishing the Pareto-optimal plan, is solved. For each patient, a single one-beam, two-beam, three-beam, etc. Pareto-optimal plan is generated until addition of beams does no longer result in significant plan quality improvement. Plan generation with iCycle is fully automated. Results: Performance and characteristics of iCycle are demonstrated by generating plans for a maxillary sinus case, a cervical cancer patient, and a liver patient treated with SBRT. Plans generated with beam angle optimization did better meet the clinical goals than equiangular or manually selected configurations. For the maxillary sinus and liver cases, significant improvements for noncoplanar setups were seen. The cervix case showed that also in IMRT with coplanar setups, beam angle optimization with iCycle may improve plan quality. Computation times for coplanar plans were around 1-2 h and for noncoplanar plans 4-7 h, depending on the number of beams and the complexity of the site. Conclusions: Integrated beam angle and profile optimization with iCycle may result in significant improvements in treatment plan quality. Due to automation, the plan generation workload is minimal. Clinical application has started.

62 RADIOLOGY AND NUCLEAR MEDICINE↗

Hysterosalpingography using a flat panel unit: Evaluation and optimization of ovarian radiation dose

Purpose: The aim of the present study was the evaluation and optimization of radiation dose to the ovaries (D) in hysterosalpingography (HSG). Methods: The study included a phantom study and a clinical one. In the phantom study, we evaluated imaging results for different geometrical setups and irradiation conditions. In the clinical study, 34 women were assigned into three different fluoroscopy modes and D was estimated with direct cervical TLD measurements. Results: In the phantom study, we used a source-to-image-distance (SID) of 110 cm and a field diagonal of 48 cm, and thus decreased air KERMA rate (KR) by 19% and 70%, respectively, for beam filtration: 4 mm Al and 0.9 mm Cu (Low dose). The least radiation exposure was accomplished by using the 3.75 pps fluoroscopy mode in conjunction with beam filtration: Low dose. In the clinical study, D normalized to 50 s of fluoroscopy time with a 3.75 pps fluoroscopy mode reached a value of 0.45 {+-} 0.04 mGy. Observers' evaluation of diagnostic image quality did not significantly differ for the three different modes of acquisition that were compared. Conclusions: Digital spot radiographs could be omitted in modern flat panel systems during HSG. Fluoroscopy image acquisitions in a modern flat panel unit at 3.75 pps and a beam filtration of 4 mm Al and 0.9 mm Cu demonstrate acceptable image quality with an average D equal to 0.45 mGy. This value is lower compared to the studied literature. For these reasons, the proposed method may be recommended for routine HSG examination in order to limit radiation exposure to the ovaries.

60 APPLIED LIFE SCIENCES↗

Intervertebral anticollision constraints improve out-of-plane translation accuracy of a single-plane fluoroscopy-to-CT registration method for measuring spinal motion

Purpose: The study aimed to propose a new single-plane fluoroscopy-to-CT registration method integrated with intervertebral anticollision constraints for measuring three-dimensional (3D) intervertebral kinematics of the spine; and to evaluate the performance of the method without anticollision and with three variations of the anticollision constraints via an in vitro experiment. Methods: The proposed fluoroscopy-to-CT registration approach, called the weighted edge-matching with anticollision (WEMAC) method, was based on the integration of geometrical anticollision constraints for adjacent vertebrae and the weighted edge-matching score (WEMS) method that matched the digitally reconstructed radiographs of the CT models of the vertebrae and the measured single-plane fluoroscopy images. Three variations of the anticollision constraints, namely, T-DOF, R-DOF, and A-DOF methods, were proposed. An in vitro experiment using four porcine cervical spines in different postures was performed to evaluate the performance of the WEMS and the WEMAC methods. Results: The WEMS method gave high precision and small bias in all components for both vertebral pose and intervertebral pose measurements, except for relatively large errors for the out-of-plane translation component. The WEMAC method successfully reduced the out-of-plane translation errors for intervertebral kinematic measurements while keeping the measurement accuracies for the other five degrees of freedom (DOF) more or less unaltered. The means (standard deviations) of the out-of-plane translational errors were less than -0.5 (0.6) and -0.3 (0.8) mm for the T-DOF method and the R-DOF method, respectively. Conclusions: The proposed single-plane fluoroscopy-to-CT registration method reduced the out-of-plane translation errors for intervertebral kinematic measurements while keeping the measurement accuracies for the other five DOF more or less unaltered. With the submillimeter and subdegree accuracy, the WEMAC method was considered accurate for measuring 3D intervertebral kinematics during various functional activities for research and clinical applications.

62 RADIOLOGY AND NUCLEAR MEDICINE↗

Rapid emission angle selection for rotating-shield brachytherapy

Purpose: The authors present a rapid emission angle selection (REAS) method that enables the efficient selection of the azimuthal shield angle for rotating shield brachytherapy (RSBT). The REAS method produces a Pareto curve from which a potential RSBT user can select a treatment plan that balances the tradeoff between delivery time and tumor dose conformity. Methods: Two cervical cancer patients were considered as test cases for the REAS method. The RSBT source considered was a Xoft Axxent{sup TM} electronic brachytherapy source, partially shielded with 0.5 mm of tungsten, which traveled inside a tandem intrauterine applicator. Three anchor RSBT plans were generated for each case using dose-volume optimization, with azimuthal shield emission angles of 90 Degree-Sign , 180 Degree-Sign , and 270 Degree-Sign . The REAS method converts the anchor plans to treatment plans for all possible emission angles by combining neighboring beamlets to form beamlets for larger emission angles. Treatment plans based on exhaustive dose-volume optimization (ERVO) and exhaustive surface optimization (ERSO) were also generated for both cases. Uniform dwell-time scaling was applied to all plans such that that high-risk clinical target volume D{sub 90} was maximized without violating the D{sub 2cc} tolerances of the rectum, bladder, and sigmoid colon. Results: By choosing three azimuthal emission angles out of 32 potential angles, the REAS method performs about 10 times faster than the ERVO method. By setting D{sub 90} to 85-100 Gy{sub 10}, the delivery times used by REAS generated plans are 21.0% and 19.5% less than exhaustive surface optimized plans used by the two clinical cases. By setting the delivery time budget to 5-25 and 10-30 min/fx, respectively, for two the cases, the D{sub 90} contributions for REAS are improved by 5.8% and 5.1% compared to the ERSO plans. The ranges used in this comparison were selected in order to keep both D{sub 90} and the delivery time within acceptable limits. Conclusions: The REAS method enables efficient RSBT treatment planning and delivery and provides treatment plans with comparable quality to those generated by exhaustive replanning with dose-volume optimization.

60 APPLIED LIFE SCIENCES↗

SU-E-T-124: Dosimetric Comparison of HDR Brachytherapy and Intensity Modulated Proton Therapy

Purpose: Brachytherapy is known to be able to deliver more radiation dose to tumor while minimizing radiation dose to surrounding normal tissues. Proton therapy also provides superior dose distribution due to Bragg peak. Since both HDR and Intensity Modulated Proton Therapy (IMPT) are beneficial for their quick dose drop off, our goal in this study is to compare the pace of dose gradient drop-off between HDR and IMPT plans based on the same CT image data-set. In addition, normal tissues sparing were also compared among HDR, IMPT and SBRT. Methods: Five cervical cancer cases treated with EBRT + HDR boost combination with Tandem and Ovoid applicator were used for comparison purpose. Original HDR plans with prescribed dose of 5.5 Gy x 5 fractions were generated and optimized. The 100% isodose line of HDR plans was converted to a dose volume, and treated as CTV for IMPT and SBRT planning. The same HDR CT scans were also used for IMPT plan and SBRT plan for direct comparison. The philosophy of the IMPT and SBRT planning was to create the same CTV coverage as HDR plans. All three modalities treatment plans were compared to each other with a set of predetermined criteria. Results: With similar target volume coverage in cervix cancer boost treatment, HDR provides a slightly sharper dose drop-off from 100% to 50% isodose line, averagely in all directions compared to IMPT. However, IMPT demonstrated more dose gradient drop-off at the junction of the target and normal tissues by providing more normal tissue sparing and superior capability to reduce integral dose. Conclusion: IMPT is capable of providing comparable dose drop-off as HDR. IMPT can be explored as replacement for HDR brachytherapy in various applications.

60 APPLIED LIFE SCIENCES↗

SU-E-T-383: Can Stereotactic Body Radiotherapy Mimic the Dose Distribution of High-Dose-Rate Tandem and Ovoids/ring Brachytherapy?

Purpose: To investigate whether stereotactic body radiotherapy (SBRT) using volumetric modulated arc therapy (VMAT) can mimic the dosimetry of tandem and ovoids/ring brachytherapy. Methods: We selected 5 patients treated with 3D-CT based high-dose rate (HDR) brachytherapy using 4 tandem and ovoid and 1 tandem and ring case. Manual optimization based on the Manchester system followed by graphical optimization (Nucletron Oncentra MasterPlan or Varian BrachyVision) was performed to deliver 6.0 Gy per fraction to a high-risk CTV while maintaining dose to organs at risk (OAR) below the ABS recommendations. For theoretical SBRT plans, CT images and OAR contours from the HDR plans were imported into Eclipse (Varian). The SBRT plan was created to mimic the heterogeneity of HDR plans by using a simultaneous integrated boost technique to match the V100, V150, and V200 isodose volumes from HDR. The OAR Dmax from HDR was used to define the OAR dose constraints for SBRT. Target coverage, dose spill-out, and OAR doses (D0.1cc, D1cc, and D2cc) between the HDR and SBRT plans were compared for significance using a two-tail paired ttest. Results: The mean isodose volumes for HDR vs. SBRT were 29.4 cc vs. 29.0 cc (V200, p = 0.674), 49.2 cc vs. 56.3 cc (V150, p = 0.017), 95.4 cc vs. 127.7 cc (V100, p = 0.001), and 271.9 cc vs. 581.6 cc (V50, p = 0.001). The D2cc to OAR for HDR vs. SBRT was 71.6% vs. 96.2% (bladder, p = 0.002), 69.2% vs. 101.7% (rectum, p = 0.0003), and 56.9% vs. 68.6% (sigmoid, p = 0.004). Conclusion: SBRT with VMAT can provide similar dose target coverage (V200), but dose spill-out and doses to OAR were statistically significantly higher than HDR. This study clearly demonstrated that brachytherapy can not be substituted with SBRT in gynecologic cervical cancer treatment.

60 APPLIED LIFE SCIENCES↗

SU-E-T-608: Performance Comparison of Four Commercial Treatment Planning Systems Applied to Intensity-Modulated Radiotherapy

Purpose: To compare the performances of four commercial treatment planning systems (TPS) used for the intensity-modulated radiotherapy (IMRT). Methods: Ten patients of nasopharyngeal (4 cases), esophageal (3 cases) and cervical (3 cases) cancer were randomly selected from a 3-month IMRT plan pool at one radiotherapy center. For each patient, four IMRT plans were newly generated by using four commercial TPS (Corvus, Monaco, Pinnacle and Xio), and then verified with Matrixx (two-dimensional array/IBA Company) on Varian23EX accelerator. A pass rate (PR) calculated from the Gamma index by OminiPro IMRT 1.5 software was evaluated at four plan verification standards (1%/1mm, 2%/2mm, 3%/3mm, 4%/4mm and 5%/5mm) for each treatment plan. Overall and multiple pairwise comparisons of PRs were statistically conducted by analysis of covariance (ANOVA) F and LSD tests among four TPSs. Results: Overall significant (p>0.05) differences of PRs were found among four TPSs with F test values of 3.8 (p=0.02), 21.1(>0.01), 14.0 (>0.01), 8.3(>0.01) at standards of 1%/1mm to 4%/4mm respectively, except at 5%/5mm standard with 2.6 (p=0.06). All means (standard deviation) of PRs at 3%/3mm of 94.3 ± 3.3 (Corvus), 98.8 ± 0.8 (Monaco), 97.5± 1.7 (Pinnacle), 98.4 ± 1.0 (Xio) were above 90% and met clinical requirement. Multiple pairwise comparisons had not demonstrated a consistent low or high pattern on either TPS. Conclusion: Matrixx dose verification results show that the validation pass rates of Monaco and Xio plans are relatively higher than those of the other two; Pinnacle plan shows slight higher pass rate than Corvus plan; lowest pass rate was achieved by the Corvus plan among these four kinds of TPS.

60 APPLIED LIFE SCIENCES↗

SU-E-T-634: Analysis of Volume Based GYN HDR Brachytherapy Plans for Dose Calculation to Organs At Risk(OAR)

Purpose: We have analyzed the dose volume histogram of 140 CT based HDR brachytherapy plans and evaluated the dose received to OAR ; rectum, bladder and sigmoid colon based on recommendations from ICRU and Image guided brachytherapy working group for cervical cancer . Methods: Our treatment protocol consist of XRT to whole pelvis with 45 Gy at 1.8Gy/fraction followed by 30 Gy at 6 Gy per fraction by HDR brachytherapy in 2 weeks . The CT compatible tandem and ovoid applicators were used and stabilized with radio opaque packing material. The patient was stabilized using special re-locatable implant table and stirrups for reproducibility of the geometry during treatment. The CT scan images were taken at 3mm slice thickness and exported to the treatment planning computer. The OAR structures, bladder, rectum and sigmoid colon were outlined on the images along with the applicators. The prescription dose was targeted to A left and A right as defined in Manchester system and optimized on geometry . The dosimetry was compared on all plans using the parameter Ci.sec.cGy-1 . Using the Dose Volume Histogram (DVH) obtained from the plans the doses to rectum, sigmoid colon and bladder for ICRU defined points and 2cc volume were analyzed and reported. The following criteria were used for limiting the tolerance dose by volume (D2cc) were calculated. The rectum and sigmoid colon doses were limited to <75Gy. The bladder dose was limited to < 90Gy from both XRT and HDR brachytherapy. Results: The average total (XRT+HDRBT) BED values to prescription volume was 120 Gy. Dose 2cc to rectum was 70Gy +/− 17Gy, dose to 2cc bladder was 82+/−32 Gy. The average Ci.sec.cGy-1 calculated for the HDR plans was 6.99 +/− 0.5 Conclusion: The image based treatment planning enabled to evaluati volume based dose to critical structures for clinical interpretation.

60 APPLIED LIFE SCIENCES↗

SU-F-19A-04: Dosimetric Evaluation of a Novel CT/MR Compatible Fletcher Applicator for Intracavitary Brachytherapy of the Cervix Uteri

Purpose: To validate a Monte Carlo model and evaluate the dosimetric capabilities of a novel commercial CT/MR compatible Fletcher applicator for cervical cancer brachytherapy. Methods: MCNPX 2.7.0 was used to model the Fletcher CT/MR shielded applicator (FA) and 192Ir HDR source. Energy deposition was calculated with a track length estimator modified by an energy-dependent heating function. A high density polystyrene phantom was constructed with three film pockets for validation of the MCNPX model. Three planes of data were calculated with the MCNPX model corresponding to the three film planes in phantom. The planes were located 1 cm from the most anterior, posterior, and medial extents of the FA right ovoid. Unshielded distributions were calculated by modeling the shielded cells as air instead of the tungsten alloy. A third order polynomial fit to the OD to dose curve was used to convert OD of the three film planes to dose. Each film and MCNPX plane dose distribution was normalized to a point 2 cm from the center of the film plane and in a region of low dose gradient. MCNPX and film were overlaid and compared with a distance-to-agreement criterion of (±2%/±2mm). Shielded and unshielded distributions were overlaid and a percent shielded plot was created. Results: 85.2%, 97.1%, and 96.6% of the MCNPX points passed the (±2%/±2mm) criterion respectively for the anterior, lateral, and posterior film comparison planes. A majority of the points in the anterior plane that exceeded the DTA criterion were either along edges of where the film was cut or near the terminal edges of the film. The percent shielded matrices indicated that the maximum % shielding was 50%. Conclusion: These data confirm the validity of the FA Monte Carlo model. The FA ovoid can shield up to 50% of the dose in the anteroposterior direction.

60 APPLIED LIFE SCIENCES↗

WE-A-16A-01: International Medical Physics Symposium: Increasing Access to Medical Physics Education/Training and Research Excellence

In response to a world in which cancer is a growing global health challenge, there is now a greater need for US Medical Physicists and other Radiation Oncology professionals across institutions to work together and be more globally engaged in the fight against cancer. There are currently many opportunities for Medical Physicists to contribute to alleviating this pressing need, especially in helping enhance access to Medical Physics Education/training and Research Excellence across international boundaries, particularly for low and middle-income countries (LMIC), which suffer from a drastic shortage of accessible knowledge and quality training programs in radiotherapy. Many Medical Physicists are not aware of the range of opportunities that even with small effort could have a high impact. Faculty at the two CAMPEP-accredited Medical Physics Programs in New England: the University of Massachusetts Lowell and Harvard Medical School have developed a growing alliance to increase Access to Medical Physics Education/training and Research Excellence (AMPERE), and facilitate greater active involvement of U.S. Medical Physicists in helping the global fight against cancer and cancer disparities. In this symposium, AMPERE Alliance members and partners from Europe and Africa will present and discuss the growing global cancer challenge, the dearth of knowledge, research, and other barriers to providing life-saving radiotherapy in LMIC, mechanisms for meeting these challenges, the different opportunities for participation by Medical Physicists, including students and residents, and how participation can be facilitated to increase AMPERE for global health. Learning Objectives: To learn about the growing global cancer challenge, areas of greatest need and limitations to accessing knowledge and quality radiotherapy training programs, especially in LMIC; To learn about the range of opportunities for Medical Physicists, including students and residents, to work together in global health to help increase AMPERE and alleviate the growing global burden of cancer; To present and discuss a new model for harmonizing Medical Physics Training across countries and how this model (UMass and Heidelberg) could be extended to LMIC in collaboration with the IAEA; To highlight a new platform and program for facilitating contributions by Medical Physicists to increase AMPERE towards the elimination of global cancer disparities. Challenges in Cancer Control in Africa Twalib A. Ngoma, MD, Professor, Executive Director, Ocean Road Cancer Institute, Dar Es Salaam, Tanzania Cancer care in Africa is beset by lack of attention, political will, cancer registries, cancer plans, human resources, financial resources and treatment facilities.. As a result of this, cancer patients in Africa are far more likely to die of their disease than those in developed countries. According to data from the WHO 750,000 new cancer cases occur in Africa every year and this number is predicted to rise by 70% by 2020. To make matters worse, an estimated 75% of cancer patients in Africa have advanced or incurable cancers at diagnosis making palliative care the most realistic approach to their management. Furthermore, Cancer prevention is nearly nonexistent, cancer detection is rare and treatment usually comes too late and is inefficient. The overall mortality-to-incidence ratio for men with cancer in the Africa is 0.75 compared with 0.54 in the developed world while the ratios for women in Africa, is 0.65 compared with 0.45 for women in the developed world. There is also limited access to radiotherapy. According to the International Atomic Energy Agency (IAEA), whilst developed countries usually have one radiotherapy machine per 250,000 people, most African nations have only one machine per ten million people. The above numbers are alarming and speak for themselves. The only solution to improve this alarming situation is to address the major challenges which African countries face in provision of cancer services which include but not limited to lack of cancer registries, lack of funding, lack of human resources, lack of radiotherapy machines, lack of cancer drugs and lack of accessible and affordable cancer screening, early diagnosis, treatment or palliative care services. Since there are considerable differences among African countries, in my presentation I will share with the audience how we address cancer control challenges in Tanzania in general and specifically in radiation oncology. The African continent cancer plan 2013 2017 Folakemi Odedina, PhD, Professor and Director of Health Disparities, UF Health Cancer Center, University of Florida The burden of cancer is rising in Africa, in addition to current heavy burden of communicable, and other non-cancer related non—communicable diseases. Conquering cancer in Africa will require a comprehensive collaborative approach with cancer clinicians, scientists, patients, advocates, policy makers and community leaders working hand-in-hand at the local, state, national, and continent levels with the primary mission: To reduce the number of deaths from cancer and improve the quality of life of cancer patients, survivors and caregivers. Unfortunately, less than 40% of African countries have a credible cancer control policy and program. The African Organization for Research and Training in Cancer (AORTIC) decided to create an African Cancer Plan to provide cost-effective strategies that can be employed throughout the continent to fight cancer. Based on the African proverb that “It takes a village to raise a child”, the Cancer Plan provides specific strategies that can be used by individuals, employers, organizations and policy-makers to fight cancer. In addition, we have provided overarching strategies to address cancer in Africa and targeted 5-year plan for prostate, breast, cervix, lung and liver cancers. In developing this Cancer Plan, our primary goal is to decrease cancer incidence and mortality in Africa. This goal can only be achieved by stakeholders and dedicated individuals to lead and implement the strategies outlined in this plan. If you are interested in partnering with AORTIC to reduce the burden of cancer in Africa, please send an email to info@aortic-africa.org. Synergies in research and clinical care through international collaboration Thomas Bortfeld and David Gierga, Massachusetts General Hospital, Harvard Medical School, MA Medical Physics relies on high technology that is not distributed equally. The whole spectrum of Medical Physics technologies is not available at every hospital or research institute, and not even in every high income country. One example is heavy ion therapy equipment which is currently only available in Japan, Germany and Italy. There is also a large global variation in terms of research infrastructure and focus. A student of Medical physics cannot gain broad experience, certainly not hands-on experience, by staying at one place only. While it is debatable what a good trade-off between breadth and depth in Medical Physics education is, it is generally agreed upon that some breadth is necessary. Researchers in Medical Physics have to cross borders if they need specific technologies for their projects. Therefore it is self-evident that international programs in Medical Physics education and research make sense. Yet, very few programs of this type exist. In this presentation we will report on our own experience of pursuing an international career in Medical Physics, with international student programs, and with the international exchange of researchers. We will present new or planned opportunities such as the medical beamline at CERN in Geneva. We will also report on the synergies in clinical care through international collaborations between partners in high and low income countries. One example is the partnership of the MGH/Harvard Medical School community with the oncology community and government of Botswana to form the BOTSOGO (BOTSwana Oncology Global Outreach) initiative. This collaborative effort in oncology care was spurred by existing relationships in HIV/AIDS research and care delivery developed within the Botswana-Harvard AIDS Institute Partnership (BHP). The initial efforts of the BOTSOGO initiative have been organized as follows: 1) on-site visits to share expertise in clinical cancer care for capacity building purposes (e.g. cervical brachytherapy), 2) developing a forum for multi-disciplinary case discussions and education and 3) relationship building with local stakeholders for long-term sustainability and growth. An international system for the certification of medical physicists Raymond K. Wu, Chairman, IOMP Professional Relations Committee; Chairman, AAPM Exchange Scientist Program Subcommittee An international system for the certification of medical physicists is an important issue. The International Organization for Medical Physicists (IOMP) has in collaboration with a number of member countries established the International Medical Physics Certification Board (IMPCB) to address this issue, and to provide a mechanism to mark the milestone for the professional development of clinical medical physicists. Raymond Wu, PhD, is the CEO of IMPCB and the Chairman of the IOMP Professional Relations Committee. He is the invited speaker recommended by IOMP to give a talk on this important subject. He will give the latest update of the work of IMPCB, its near term goals, and pathways to the goals. He will also discuss the importance of such an International System of certification in the training/education of next generation Medical Physicists, including those in low and middle income countries (LMIC) where such training is crucial in the fight against cancer. Learning Objectives: Understand the certification program as described in the IOMP Policy Statements. Understand the plan of the IMPCB to establish the accreditation process of national certification programs. Understand the goals of this international collaborative effort and the potential impacts to the quality of clinical medical physics practice. Medical Physics Education Across Continents: The UMass Lowell and Heidelberg University Joint Coordination Effort Erno Sajo, Director of Medical Physics, University of Massachusetts at Lowell Medical Physics education has unique flavors across institutions within the US and shows significant differences across continents. In the latter, even the definition of Medical Physics may differ. Not only is there a difference in topical coverage, but often what is considered a cohesive topic in one institution, and taught as a single course, is fragmented among several other courses in the other institution due to a different philosophy. Because of the regulatory and certification requirements, these differences impact the mobility of medical physicists across continents. As a result, physicists who wish to practice in the US or Canada but have completed their education elsewhere often find that they have to take remedial courses or even obtain a new degree in Medical Physics despite the fact that they already have one. Outreach to developing countries, therefore, is even more difficult. The University of Massachusetts Lowell and Heidelberg University recently completed a joint coordination effort, in which they identified topics that are common versus complementary in their medical physics curricula. A student exchange program was developed that permits students to take any of the common topics at the other institution while taking complementary courses as electives, which count towards their degree requirements at their home institution. Thesis research is also mutually accepted. When properly documented, in this way CAMPEP recommendations can be met across the institutions. Therefore, students participating in this program satisfy both the American Board of Radiology (ABR) requirements and the European regulatory requirements. The framework on which this collaboration rests and the cross-comparison methods developed therein may be implemented in other exchange programs and thus a similar approach can be adopted in outreach programs with developing countries. IAEA PACT Program and opportunities for support and collaboration Susan Morgan, Program Coordinator, International Atomic Energy Agency, Vienna, Austria In response to the developing world's cancer crisis, the International Atomic Energy Agency (IAEA) established the Program of Action for Cancer Therapy (PACT) in 2004 to fully realize the public health impact obtained through global partnerships in cancer control and technology transfer in radiation medicine. PACT's vision strives for global partnerships to confront the cancer crisis in developing countries, notably with our sister United Nations agency, the World Health Organization (WHO), and our Joint Programme on Cancer Control established in 2009. The IAEA, through PACT, the WHO, the International Agency for Research on Cancer (IARC) and other cancer-related organizations work together to make a coordinated global response in supporting low and middle income (LMI) IAEA Member States in the implementation of comprehensive national cancer control programmes. PACT's goals are: To build global partnerships of cancer-related organizations committed to addressing the challenge of cancer in LMI Member States in all its aspects; To mobilize resources from charitable trusts, foundations, and others in public and private sectors sources to assist LMI Member States to develop and implement their radiation medicine capacities within a national cancer control programme (NCCP); and, To ensure the effective and sustainable transfer of radiation medicine technologies or knowledge to all LMI Member States where unmet needs exist. PACT work focuses on: imPACT: Assessing Cancer Burden PMDS: Developing Global Partnerships VUCCnet: Promoting Cancer Control Training AGaRT: Making Radiotherapy Accessible Facilitating increased participation and professional development of Medical Physicists and other Radiation Oncology professionals in global health Wilfred Ngwa, Harvard Medical School, University of Massachusetts Lowell, MA The 2014 World Health Organization (WHO) Cancer report highlights an alarming increase in the global burden of cancer. It also highlights what it terms “the cancer divide”, or disparities, evinced by a substantially higher cancer burden in low and middle income countries (LMIC) in Asia, Central/South America and Africa. The WHO even predicts a potential African cancer epidemic by 2020 if significant progress is not made in global cancer control efforts. Evidence that collaborative global health approaches have led to major progress in controlling infectious diseases including in LMIC suggests that similar approaches will be useful for non-communicable diseases like cancer. In consonance with this, leaders in cancer policy from the USA and 14 economically diverse countries recently concluded that successful campaigns to control cancers with existing methods and to improve current strategies will increasingly depend onconcerted multinational collaborations (Sci Transl Med 5, p. 175, 2013). Hence there is growing urgency for increasing collaborative global cancer Care Research and Education (CaRE), as well as support for greater effectiveness of already existing initiatives involving partners from different nations, diverse economic and cultural backgrounds. The good news is that there is a growing awareness of the importance of global health and growing interest including amongst Medical Physicists and other Radiation oncology (RadOnc) professionals to participate in global health. However, many are unaware of currently existing opportunities for participation that even with small effort could have a high impact. Over 50% of cancer patients in the developed world depend on RadOnc professionals for their treatment, and hence participation of RadOnc professionals in global health efforts in the global fight against cancer is crucial. It is also important that the next generation of RadOnc professionals (students, and residents) be trained with a global perspective, to be global health leaders in cancer CaRE. This presentation will highlight a novel platform for enhancing participation and professional development of Medical Physicists and other RadOnc professionals in global health. Ways in which this platform can facilitate contributions by Medical Physicists and other RadOnc Professionals, students and residents in global health towards the elimination of global cancer disparities will be discussed. This will be followed by a panel discussion by some of the pioneers/leaders in collaborative global cancer CaRE on the growing cancer burden, challenges and opportunities for greater active involvement and professional development.

60 APPLIED LIFE SCIENCES↗

WE-F-BRD-01: HDR Brachytherapy II: Integrating Imaging with HDR

In recent years, with the advent of high/pulsed dose rate afterloading technology, advanced treatment planning systems, CT/MRI compatible applicators, and advanced imaging platforms, image-guided adaptive brachytherapy treatments (IGABT) have started to play an ever increasing role in modern radiation therapy. The most accurate way to approach IGABT treatment is to provide the infrastructure that combines in a single setting an appropriate imaging device, a treatment planning system, and a treatment unit. The Brachytherapy Suite is not a new concept, yet the modern suites are incorporating state-of-the-art imaging (MRI, CBCT equipped simulators, CT, and /or US) that require correct integration with each other and with the treatment planning and delivery systems. Arguably, an MRI-equipped Brachytherapy Suite is the ideal setup for real-time adaptive brachytherapy treatments. The main impediment to MRI-IGABT adoption is access to MRI scanners. Very few radiation oncology departments currently house MRI scanners, and even fewer in a dedicated Brachytherapy Suite. CBCT equipped simulators are increasingly offered by manufacturers as part of a Brachytherapy Suite installation. If optimized, images acquired can be used for treatment planning, or can be registered with other imaging modalities. This infrastructure is relevant for all forms of brachytherapy, especially those utilizing multi-fractionated courses of treatment such as prostate and cervix. Moreover, for prostate brachytherapy, US imaging systems can be part of the suite to allow for real-time HDR/LDR treatments. Learning Objectives: Understand the adaptive workflow of MR-based IGBT for cervical cancer. Familiarize with commissioning aspects of a CBCT equipped simulator with emphasis on brachytherapy applications Learn about the current status and future developments in US-based prostate brachytherapy.

60 APPLIED LIFE SCIENCES↗

TH-C-BRD-11: Robustness of Pencil Beam Scanning Proton Therapy for Pelvic Cancer Under Anatomical Changes

Purpose: Pencil beam scanning (PBS) proton therapy provides excellent dosimetric benefits in pelvic cancer treatment, yet day-to-day anatomical variations in pelvic region tend to cause range uncertainties. This study evaluates the dosimetric robustness under anatomical changes for three PBS intensity-modulated proton therapy (IMPT), IMPT using worstcase robust optimization (thereafter ‘Robust IMPT’), and single-field uniform dose (SFUD), in cervical cancer treatment. Methods: IMPT, Robust IMPT, and SFUD plans using the same beam directions and the same prescription (Rx) were generated on computed tomography (CT) images acquired on the simulation day. The dose from each plan was then recomputed on CT images acquired in subsequent two to five weeks using the same protocol. The weekly CTs were registered to the planning CT based on bony anatomy. Target coverage was considered adequate on each weekly CT if dose to 99% of the internal target volume (D-ITV99%) reached at least 95% of the Rx dose. Statistical analysis was then performed on the 21 weekly CT images available for the 7 enrolled patients. Results: Statistically, IMPT was unable to maintain target coverage (mean D-ITV99% = 90.5% Rx, p = 0.004), and SFUD was able to maintain target coverage (mean D-ITV99% = 98.0% Rx, p = 0.0064), in the weeks following simulation. Robust IMPT was able to improve the robustness of IMPT significantly (p < 0.0001), though its maintenance of target coverage was not statistically significant by the 95% Rx criteria (mean D-ITV99% = 96.0%, p = 0.1677). Conclusion: During the multi-week treatment course with anatomical variations, SFUD is robust in terms of maintaining target coverage while IMPT is not. The worst-case optimized Robust IMPT, assuming ±3.5% range uncertainties, improves the robustness of IMPT under anatomical changes significantly, even though it was not designed to account for anatomical changes by mechanism.

60 APPLIED LIFE SCIENCES↗

Asymmetric dose–volume optimization with smoothness control for rotating-shield brachytherapy

Purpose: It is important to reduce fluence map complexity in rotating-shield brachytherapy (RSBT) inverse planning to improve delivery efficiency while maintaining plan quality. This study proposes an efficient and effective RSBT dose optimization method which enables to produce smooth fluence maps. Methods: Five cervical cancer patients each with a high-risk clinical-target-volume (HR-CTV) larger than 40 cm{sup 3} were considered as the test cases. The RSBT source was a partially shielded electronic brachytherapy source (Xoft Axxent™). The anchor RSBT plans generated by the asymmetric dose–volume optimization with smoothness control (ADOS) method were compared against those produced by the dose–surface optimization (DSO) method and inverse-planning with simulated annealing (IPSA). Either L{sub 1}-norm or L{sub 2}-norm was used to measure the smoothness of a fluence map in the proposed ADOS method as one weighted term of the objective function. Uniform dwell-time scaling was applied to all plans such that HR-CTV D{sub 90} was maximized without violating the D{sub 2cc} tolerances of the rectum, bladder, and sigmoid colon. The quality of the anchor plans was measured with HR-CTV D{sub 90} of the anchor plans. Single-shielded RSBT [(S-RSBT), RSBT with single, fix sized delivery window] and dynamic-sheilded RSBT [(D-RSBT), RSBT with dynamically varying sized delivery window] delivery plans generated based on the anchor plans were also measured, with delivery time constraints of 10, 20, and 30 min/fraction (fx). Results: The average HR-CTV D{sub 90} values of the anchor plans achieved by the ADOS, DSO, and IPSA methods were 111.5, 94.2, and 107.4 Gy, respectively, where the weighting parameter β used in ADOS with L{sub 2}-norm was set to be 100. By using S-RSBT sequencing and 20 min/fx delivery time, the corresponding D{sub 90} values were 88.8, 81.9, and 83.4 Gy; while using D-RSBT sequencing with 20 min/fx delivery time, the corresponding D{sub 90} values were 91.4, 88.3, and 78.9 Gy, respectively. The average optimization times for ADOS, DSO, and IPSA were, respectively, 77, 4, and 1800 s. By using L{sub 1}-norm instead of L{sub 2}-norm in the ADOS method, the optimization time was increased by 20 s, while the D{sub 90} was reduced by 6.8 Gy on average. ADOS-L1 was found to be more sensitive to the weighting parameter than ADOS-L2. If β was increased to 10 000, the D{sub 90} drop with ADOS-L1 was 38 Gy, while the drop with ADOS-L2 is 13 Gy. Conclusions: The ADOS method had a reasonable optimization time cost, while achieving comparable RSBT dose plans as the IPSA method, which is of much higher time complexity. Compared to the DSO and IPSA methods, ADOS is able to generate anchor plans which are more suitable for RSBT delivery while preserving the high quality of the original plans. Compared to ADOS-L1, ADOS-L2 is able to achieve better quality of anchor plans more efficiently.

60 APPLIED LIFE SCIENCES↗